PriceTargets.com logo

Zura Bio - ZURA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $14.67
  • Forecasted Upside: 897.73%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 1 Strong Buy Ratings
$1.47 As of 05/2/2025 05:00 PM ET
+0 (0.00%)

This chart shows the closing price for ZURA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
MarApr$1.47Closing price on 05/02/25:
Get New Zura Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZURA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZURA

Analyst Price Target is $14.67
▲ +897.73% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Zura Bio in the last 3 months. The average price target is $14.67, with a high forecast of $26.00 and a low forecast of $3.00. The average price target represents a 897.73% upside from the last price of $1.47.

This chart shows the closing price for ZURA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
4/247/2410/241/255/255/26$0.72$7.04$13$20$26Closing price on 05/02/25: $1.47High$26.00Average$14.67Low$3.00




Current Consensus is Buy

The current consensus among 8 contributing investment analysts is to buy stock in Zura Bio. This rating has held steady since November 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2023
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/7/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/5/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2025
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/2/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2025

Latest Recommendations

  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/3/2025HC WainwrightReiterated RatingBuy ➝ Buy
4/3/2025HC WainwrightLower TargetNeutral ➝ Neutral$5.00 ➝ $3.00
3/26/2025OppenheimerReiterated RatingOutperform ➝ Outperform$20.00 ➝ $19.00
3/26/2025GuggenheimReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
3/26/2025Chardan CapitalLower TargetBuy ➝ Buy$12.00 ➝ $10.00
12/24/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$5.00 ➝ $5.00
12/11/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight
11/18/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$5.00 ➝ $5.00
11/11/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$5.00 ➝ $5.00
11/8/2024Chardan CapitalLower TargetBuy ➝ Buy$14.00 ➝ $12.00
11/4/2024Leerink PartnrsUpgradeStrong-Buy
11/4/2024Leerink PartnersInitiated CoverageOutperform$15.00
10/21/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$5.00 ➝ $5.00
10/18/2024Cantor FitzgeraldReiterated RatingOverweight
9/19/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$26.00 ➝ $26.00
9/5/2024HC WainwrightInitiated CoverageNeutral$5.00
8/15/2024Cantor FitzgeraldReiterated RatingOverweight
6/12/2024Cantor FitzgeraldInitiated CoverageOverweight
5/10/2024OppenheimerBoost TargetOutperform ➝ Outperform$16.00 ➝ $21.00
5/3/2024Piper SandlerInitiated CoverageOverweight$26.00
4/1/2024OppenheimerReiterated RatingOutperform ➝ Outperform$17.00 ➝ $16.00
10/10/2023LADENBURG THALM/SH SHInitiated CoverageBuy$10.00
8/24/2023OppenheimerInitiated CoverageOutperform$17.00
8/17/2023Chardan CapitalReiterated RatingBuy
8/15/2023Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$20.00 ➝ $22.00
7/10/2023Chardan CapitalReiterated RatingBuy
6/22/2023GuggenheimInitiated CoverageBuy$20.00
6/14/2023Chardan CapitalInitiated CoverageBuy$14.00
5/24/2023Raymond JamesInitiated CoverageStrong-Buy$20.00
(Data available from 5/2/2020 forward)

News Sentiment Rating

0.69 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 10 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2024
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2024
  • 8 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/2/2025
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/1/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/3/2025
  • 4 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
4/2/2025
  • 3 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
5/2/2025

Current Sentiment

  • 3 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Zura Bio logo
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
Read More

Today's Range

Now: $1.47
Low: $1.44
High: $1.53

50 Day Range

MA: $1.27
Low: $1.03
High: $1.54

52 Week Range

Now: $1.47
Low: $0.97
High: $6.35

Volume

230,943 shs

Average Volume

388,005 shs

Market Capitalization

$100.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.08

Frequently Asked Questions

What sell-side analysts currently cover shares of Zura Bio?

The following Wall Street analysts have issued reports on Zura Bio in the last twelve months: Cantor Fitzgerald, Chardan Capital, Guggenheim, HC Wainwright, Leerink Partners, Leerink Partnrs, Oppenheimer Holdings Inc., and Piper Sandler.
View the latest analyst ratings for ZURA.

What is the current price target for Zura Bio?

0 Wall Street analysts have set twelve-month price targets for Zura Bio in the last year. Their average twelve-month price target is $14.67, suggesting a possible upside of 897.7%. Piper Sandler has the highest price target set, predicting ZURA will reach $26.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $3.00 for Zura Bio in the next year.
View the latest price targets for ZURA.

What is the current consensus analyst rating for Zura Bio?

Zura Bio currently has 7 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ZURA will outperform the market and that investors should add to their positions of Zura Bio.
View the latest ratings for ZURA.

What other companies compete with Zura Bio?

Other companies that are similar to Zura Bio include Oruka Therapeutics, Kamada, Revance Therapeutics, Tectonic Therapeutic and Taysha Gene Therapies. Learn More about companies similar to Zura Bio.

How do I contact Zura Bio's investor relations team?

Zura Bio's physical mailing address is C/O Maples Corporate Services Limited, Po Box 309 Ugland House, Grand Cayman KY1-11. The company's listed phone number is 858-247-0520 and its investor relations email address is annemarie.fields@sternir.com. The official website for Zura Bio is www.jattacquisition.com. Learn More about contacing Zura Bio investor relations.